Anlon Healthcare Q3 PAT at 515.54L, Revenue drops 32% YoY, CFO and Director changes
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.4 pts less than Nifty Microcap 250 and 2.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board meeting on Feb 9, 2026 approved Q3 FY26 results. Q3 revenue fell to 3,557.80 lakhs from 5,220.13 lakhs YoY, a 32% drop. Q3 PAT was 515.54 lakhs vs 931.73 lakhs. 9M PAT was 1,801.96 lakhs. CFO Hitesh Makwana resigned due to pre-occupation; Naimish Bhatt named new CFO. Independent Director Shailesh Thakkar resigned citing health issues; Kishan Raja appointed as new Independent Director. IPO funds of 12,103 lakhs used as planned.
Weak Q3 results with sharp revenue and profit decline may pressure stock. Management changes add uncertainty.